Max Isaacman

About Max Isaacman

Max Isaacman is an Investment Advisor Representative in San Francisco. His investment books were published by McGraw-Hill and Financial Times Press, including the first book on ETFs, How to be an Index Investor (McGraw-Hill, 2000). He wrote for the Emmy award-winning Website His email is

Recent Articles

Clover Health’s Earnings Losses Make It One to Avoid for Now

CLOV stock should not be bought until it has positive earnings. The company has good growth to report but needs earnings to lower the risk.

3 Stocks to Buy (And 4 to Skip) in This Small-Cap Value ETF

Times are tough for small-cap stocks, but you can still find some great stocks to buy in funds focused on these smaller companies.

Matterport’s Japan Expansion Doesn’t Make It a Buy

Matterport has a lot of potential, but until that potential becomes results, MTTR stock should be left alone.

GEVO Lands a Big Client But Isn’t a Buy Yet

Delta is working with Gevo for a greener tomorrow, but until the agreement meaningfully boosts its financials, GEVO stock isn't quite a buy.

SoFi Is a Battered but Promising Company You Can Buy for Cheap

Its earnings are negative and it's had a rough 2022 so far, but SOFI stock is at 52-week lows and still has a solid business.